Related Experiment Video
Updated: Dec 26, 2025
13:10
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
Published on: September 25, 2016
10.2K
Formulation and Characterization of Antithrombin Perfluorocarbon Nanoparticles.
Alexander J Wilson1, Qingyu Zhou2, Ian Vargas1
1The USF Health Heart Institute, University of South Florida, Tampa, FL, USA.
Methods in Molecular Biology (Clifton, N.J.)
|March 11, 2020
Summary
Researchers developed novel antithrombin nanoparticles using bivalirudin and PPACK. These nanoparticles offer targeted anticoagulation, potentially reducing bleeding risks associated with thrombosis treatments.
Area of Science:
- Biochemistry
- Nanotechnology
- Pharmacology
Background:
- Thrombin is a key protein in blood clotting, crucial for thrombosis development.
- Antithrombin nanoparticles offer a promising strategy for localized anticoagulation, minimizing systemic bleeding risks.
Purpose of the Study:
- To describe the synthesis and characterization of bivalirudin and D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone (PPACK) nanoparticles.
- To evaluate the potential of these nanoparticles for site-specific anticoagulation.
Main Methods:
- Nanoparticle synthesis involving bivalirudin and PPACK.
- Characterization techniques including particle size analysis and zeta potential measurement.
- Quantification of drug loading for PPACK and bivalirudin within nanoparticles.
Main Results:
- Successful fabrication of bivalirudin and PPACK nanoparticles.
- Detailed characterization data regarding particle size, zeta potential, and drug loading efficiency.
- Established methods for nanoparticle quality control.
Conclusions:
- Bivalirudin and PPACK nanoparticles can be successfully synthesized and characterized.
- These nanoparticles represent a viable platform for targeted anticoagulation therapies.
- Further research is warranted to explore their in vivo efficacy and safety profile.
